Experimental drug targets deadly brain virus in small trial
NCT ID NCT07511049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the safety of brincidofovir, an antiviral drug, in 24 adults with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Participants receive the drug intravenously twice a week for up to 12 weeks, with follow-up for one year. The goal is to see if the drug is safe and can reduce the virus in spinal fluid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brincidofovir (an antiviral drug given intravenously)
What this could lead to
If it works, this could point toward a treatment for PML, a rare and often fatal brain infection with no approved therapies.
What could go wrong
This is a small, early-phase pilot study with only 24 participants, so results may not apply broadly. The drug may cause serious side effects or fail to control the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••